about
Spread of artemisinin resistance in Plasmodium falciparum malariaArtemisinin Resistance in Plasmodium falciparum MalariaClinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introductionReduced susceptibility of Plasmodium falciparum to artesunate in southern MyanmarEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquinePharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataPopulation Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.Statistical power calculations for mixed pharmacokinetic study designs using a population approachPharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrinePopulation pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda.Intrahost modeling of artemisinin resistance in Plasmodium falciparumOpen-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjectsOrally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover studyOptimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malariaA small amount of fat does not affect piperaquine exposure in patients with malaria.Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria.Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsPharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical AssessmentRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina FasoPopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsNaïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects.The role of previously unmeasured organic acids in the pathogenesis of severe malaria.Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malariaOptimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malariaOpposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study.
P50
Q21032481-C2F23D10-E3DC-428C-A501-5F51CFFB9BEAQ22061852-437E1156-A284-44D7-988F-11B741368E9FQ28125932-573B8AFE-2562-4DDB-BAA8-C9CD3DD67E74Q28487881-12BCE4C7-35B7-452A-A073-3437EBC98338Q28542034-0BBFA0E1-D296-4821-B69E-83C27390138EQ30357189-361613D6-7837-42D6-A74D-6FB861DC04C2Q30936416-2841EB45-C751-470A-B73C-045ED6073F68Q31153944-0BA7674F-B7A3-4105-A573-E0DAA9369FA0Q33601831-FC618A33-FE24-4F44-BF19-349231E23BDBQ33622892-538E606E-47FB-4F53-98B8-301ACB773CDAQ33882905-4D9F9FB3-DB4A-4EA3-9C59-4206DFA952BFQ33903438-36774A01-4B30-49B7-AFF1-0640E98E54FBQ34034413-00DF8AC2-09D9-4175-B8E4-8D774F2CDCB2Q34057403-1BD7FDD2-E786-4101-9C81-C3249E5EE9DFQ34099750-47943E63-C01A-4520-8376-DFCD23A4FED9Q34221884-4C4205E8-50A7-4C8B-92EF-1C69C2A25FBDQ34331026-8288A27A-2A1F-44B9-A9C9-17FF254149B2Q34471842-46137B8D-910D-4F83-AEC5-D35C96082160Q34597891-03F6C9CD-004E-40A2-BEC3-A55707E53910Q34677891-22D6FF28-3582-4467-B8F7-BB0B53677BA1Q34922652-A49E58D5-E4B0-4F2A-8D76-97CCFB63902CQ35056250-B2A444D2-F8DC-4E0F-BFC6-6BE170F22B51Q35163623-502FB812-60AB-4B51-B00E-00E64DC38ADFQ35191426-807DD0EE-6978-4287-8727-9B38DADD11CCQ35191473-6C89C0A2-060C-4739-93E1-CF029C45C49AQ35286119-9DA9BC4C-5C2A-437B-9317-3842B9008C63Q35598379-A9061AE9-2660-4E7C-B451-72A3EAAB57C5Q35806356-3992D7F6-5DDB-4D19-B3D4-CFBC9313AAF0Q35859839-38DB89EE-BB5A-4F0E-B9FB-D2A52416A708Q35859844-D175A344-87B8-4377-817D-DC644555F747Q35867343-82A60EB5-AF83-48ED-8A6A-483DF1F0854FQ35883504-4C8AA3CC-04B5-429E-A64C-25ABA6589AE3Q35978007-5528512E-7DFE-41AC-9FA9-8AE9C8717AC1Q36017416-D34E74F4-CAFC-44A8-9020-AB93D6CEA993Q36032306-1EA61D09-DB4E-4984-B267-12F8288094A3Q36075976-6B1A4ACD-7CC7-492B-AE97-694935C2FA59Q36080121-85DD016A-17CE-435C-9A4B-58E0E6AEFCAAQ36088256-3AF0FB8F-6D61-4C5A-BBB9-5D267ED505FDQ36125445-426C7A4A-CE67-4C69-B2F6-9D0064BF55E2Q36166714-0605808D-D908-4E59-B3A2-780125F8ADBC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joel Tarning
@ast
Joel Tarning
@en
Joel Tarning
@es
Joel Tarning
@nl
Joel Tarning
@sl
type
label
Joel Tarning
@ast
Joel Tarning
@en
Joel Tarning
@es
Joel Tarning
@nl
Joel Tarning
@sl
prefLabel
Joel Tarning
@ast
Joel Tarning
@en
Joel Tarning
@es
Joel Tarning
@nl
Joel Tarning
@sl
P106
P21
P31
P496
0000-0003-4566-4030